Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Atara Biotherapeutics develops allogeneic T-cell immunotherapies targeting Epstein-Barr virus (EBV)-associated diseases, primarily focusing on its approved product Ebvallo (tab-cel) for EBV-positive post-transplant lymphoproliferative disease (PTLD). Leveraging a proprietary EBV T-cell platform, Atara creates off-the-shelf treatments designed for rapid delivery to immunocompromised patients. The company partners with Pierre Fabre for commercialization in Europe and select global markets, operating through licensing, manufacturing, and royalty-based revenue models.
This description was generated via AI from an annual report. Updated about 1 year ago.